Transparent cleanser
US-2024299271-A1 · Sep 12, 2024 · US
US9827323B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9827323-B2 |
| Application number | US-201113155111-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 7, 2011 |
| Priority date | Jun 7, 2010 |
| Publication date | Nov 28, 2017 |
| Grant date | Nov 28, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are compositions comprising collagen covalently bound to particles, wherein covalent bonds are formed between reactive groups of the collagen and reactive groups of the particles, and wherein the particles have an average particle diameter ranging from 20 to 1000 nanometers. Also disclosed are various methods that utilize the compositions.
Opening claim text (preview).
The invention claimed is: 1. A composition comprising collagen covalently bound to particles, wherein covalent amide bonds are formed between free carboxylic acid groups of isolated or purified collagen and amine reactive groups of the particles, wherein the particles have an average particle diameter size ranging from 50 to 1000 nanometers, and wherein collagen is not cross-linked through the particles, and wherein the particles comprise ceramic material, biodegradable material, or metallic material of gold, silver, platinum, titanium, nickel, or copper. 2. The composition of claim 1 , wherein the collagen is cross-linked through the collagen. 3. The composition of claim 2 , wherein the cross-linked collagen is porous and has an average pore size ranging from 500 nanometers to 200 micrometers or from 1 micrometer to 100 micrometers. 4. The composition of claim 2 , wherein the collagen is cross-linked with a carbodiimide cross-linking agent. 5. The composition of claim 1 , wherein the particles have an average particle diameter between 50 and 150 nanometers. 6. The composition of claim 1 , wherein the amine reactive groups are mercapto ethyl amine or cystamine or both. 7. The composition of claim 1 , wherein the ratio of particles to collagen is a range of 1×10 9 particles per mg of collagen to 2×10 10 particles per mg of collagen. 8. The composition of claim 1 , further comprising embryonic stem cells, adult stem cells, induced pluripotent stem cells, epithelial cells, exocrine or endocrine cells, myoblasts, fibroblasts, osteoblasts, chondroblasts, stromal cells, hepatocytes, islet cells, neuroblasts, keratinocytes, osteoclasts, osteocytes, cardiac cells, chondrocytes, endothelial cells, or muscle cells, or any combination thereof. 9. The composition of claim 1 , wherein the composition is a gel, solution, paste, or dehydrated rigid structure. 10. The composition of claim 1 , wherein the composition is comprised in a syringe. 11. The composition of claim 1 , wherein the composition is a dermal or epidermal skin-equivalent. 12. The composition of claim 1 , wherein 15 to 20% of the free carboxylic acid groups of the collagen are covalently bound to the particles through an amide bond. 13. A method for bulking articular cartilage by increasing tissue volume in a person, comprising administering to a person in need thereof the composition of claim 1 , wherein the composition is administered by injection into a joint capsule. 14. The method of claim 13 , wherein the collagen is cross-linked and porous and has an average pore size ranging from 500 nanometers to 200 micrometers. 15. The method of claim 14 , wherein the particles have an average particle diameter between 50 and 150 nanometers. 16. The method of claim 13 , wherein the reactive group is mercapto ethyl amine or cystamine or both. 17. The method of claim 13 , wherein the ratio of particles to collagen is a range of 1×10 9 particles per 1 mg of collagen to 2×10 10 particles per 1 mg of collagen. 18. The method of claim 13 , wherein the composition is a gel, solution, paste, or dehydrated rigid structure. 19. The method of claim 13 , wherein 15 to 20% of the free carboxylic acid groups of the collagen are covalently bound to the particles through an amide bond. 20. The method of claim 13 , wherein 2 to 4 mg of a carbodiimide cross-linking agent per 30 mg of collagen is used to form the covalent bonds. 21. The method of claim 13 , wherein 0.5 to 0.2 mg of a carbodiimide cross-linking agent per 1×10 9 -2×10 10 particles is used to form the covalent bonds. 22. A method for filling voids, defects, or increasing tissue volume in a person, comprising administering to a person in need thereof the composition of claim 1 , wherein the composition is administered by intradermal or subcutaneous injection. 23. The method of claim 22 , wherein the void is a facial fine line, wrinkle, crease, pit, or nodule, and wherein the appearance of the facial fine line, wrinkle, crease, pit, or nodule is reduced after administration of the composition. 24. The method of claim 22 , wherein the composition is administered to a person's lip, and wherein the volume of the lip is increased after administration of the composition. 25. The composition of claim 1 , wherein the covalent amide bonds are formed between free carboxylic acid groups of isolated or purified soluble collagen and amine reactive groups of the particles. 26. The composition of claim 1 , wherein the collagen is injectible. 27. The composition of claim 1 , wherein the collagen is soluble. 28. The composition of claim 1 , wherein the collagen is not electrospun.
Drugs for skeletal disorders · CPC title
Drugs for dermatological disorders · CPC title
Anti-ageing preparations · CPC title
by macromolecular compounds · CPC title
with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.